Expanded access to triheptanoin
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This program provides triheptanoin, a dietary oil that may help manage certain inherited metabolic conditions, to people who cannot join a clinical trial. If you qualify, you may access this treatment through your doctor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are not able to join the main clinical trial for triheptanoin.
- You have a condition that triheptanoin is intended to treat.
- Your doctor agrees to provide the treatment and monitor you.
- You are willing to follow the treatment plan and attend necessary visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oil called triheptanoin for children with a rare genetic condition (PDCD) that affects how their bodies use energy. The study aims to see if triheptanoin can help improve their health.
This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.
This Phase 2 trial studies how well and how safely orlistat works over the long term for people who have very high triglycerides linked to rare genetic lipid disorders. It may help lower triglycerides and assess long-term side effects, but you must meet specific genetic, lab, and health requirements.
This trial tests an investigational medication, MAR001, to see if it can lower high levels of fats in the blood (triglycerides and remnant cholesterol) linked to heart disease. If you have these conditions, this treatment might help reduce your risk.
This trial is for people with a specific inherited form of amyloidosis caused by a change in the TTR gene. It offers a comprehensive care program to help manage this rare condition.
This study tests an investigational medication called DR10624 for people with very high triglycerides, a type of fat in the blood that can increase the risk of heart problems and pancreatitis. The trial aims to see if this drug can safely lower triglycerides better than standard care.
Hear when a new Long Chain Fatty Acid Oxidation Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.